Kymera Therapeutics Inc
Research Kymera Therapeutics Inc (KYMR) on Bullrun: market cap USD 8.99B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKYMR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.99B
- Financial periodFY2025
- RevenueUSD 39.21M
- Revenue growth-16.7%
- Net incomeUSD 311.35M
- Free cash flow-USD 234.34M
- Gross margin0.0%
Valuation Snapshot
latest market cap is USD 8.99B.
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others;
Frequently asked questions
What is Kymera Therapeutics Inc's market cap?
Kymera Therapeutics Inc's market capitalization is USD 8.99B.
What does Kymera Therapeutics Inc do?
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system.